Table 3.
Multivariable analysis for cancer recurrence and all-cause mortality after model selection
| Cancer recurrence | All-cause mortality | ||||||
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| EA vs non-EA | 0.927 | 0.755 to 1.139 | 0.473 | EA vs non-EA | 0.811 | 0.582 to 1.129 | 0.214 |
| Sex (M vs F) | 1.297 | 1.026 to 1.642 | 0.030 | Sex (M vs F) | 1.969 | 1.344 to 2.882 | 0.001 |
| Pretreatment CEA* | 1.263 | 1.046 to 1.524 | 0.015 | ECOG PS≥1 | 1.494 | 1.105 to 2.019 | 0.009 |
| Postoperative C/T | 1.456 | 1.187 to 1.786 | <0.001 | Pretreatment CEA* | 1.672 | 1.221 to 2.290 | 0.001 |
| Postoperative R/T | 1.443 | 1.126 to 1.849 | 0.004 | pRBC transfusion | 1.402 | 1.008 to 1.948 | 0.045 |
| Stage | <0.001 | Postoperative R/T | 1.810 | 1.271 to 2.578 | 0.001 | ||
| II vs I | 1.927 | 1.521 to 2.440 | <0.001 | Stage | <0.001 | ||
| III vs I | 2.848 | 2.265 to 3.581 | <0.001 | II vs I | 2.059 | 1.388 to 3.054 | <0.001 |
| Tumour differentiation | <0.001 | III vs I | 2.964 | 2.032 to 4.323 | <0.001 | ||
| Moderate vs good | 3.752 | 1.919 to 7.338 | <0.001 | Tumour differentiation | 0.014 | ||
| Poor vs good | 5.198 | 2.632 to 10.265 | <0.001 | Moderate vs good | 4.718 | 1.153 to 19.310 | 0.031 |
| Microscopic necrosis | 1.444 | 1.203 to 1.733 | <0.001 | Poor vs good | 6.169 | 1.487 to 25.587 | 0.012 |
| Lymphovascular invasion | 2.053 | 1.717 to 2.456 | <0.001 | Microscopic necrosis | 1.378 | 1.037 to 1.831 | 0.027 |
*On base-10 logarithmic scale.
C/T, chemotherapy; CEA, carcinoembryonic antigen; EA, epidural analgesia; ECOG PS, Eastern Cooperative Oncology Group performance score; M, male; F, female; pRBC, packed red blood cell; R/T, radiotherapy.